Anat Galor, MD
Ophthalmology · Miami, FLNPI 1962452813
Payments from drug & device makers
Across 178 payments — averaging $1851.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$110K
- Novartis$92K
- Regeneron$61K
- Dompe US, Inc.$23K
- Alcon Research LLC$13K
- Ocular Therapeutix, Inc.$8K
- plus $24K from 21 others
What the payments were for
- Consulting fees$47,19467%
- Speaking & faculty fees$13,99120%
- Travel & lodging$5721%
- Food & beverage$8,44212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 15 | $109,767 |
| Novartis | 11 | $91,713 |
| Regeneron | 35 | $60,903 |
| Dompe US, Inc. | 29 | $22,925 |
| Alcon Research LLC | 3 | $12,500 |
| Ocular Therapeutix, Inc. | 2 | $7,800 |
| Alcon | 18 | $5,771 |
| AbbVie(2 entities) | 10 | $4,348 |
| Astrazeneca UK Limited | 1 | $2,148 |
| Amgen | 2 | $2,043 |
| Heidelberg Engineering, Inc. | 2 | $2,000 |
| Janssen Research & Development, LLC | 3 | $1,700 |
| Daiichi Sankyo Inc. | 1 | $1,611 |
| Bausch & Lomb Americas Inc. | 5 | $877 |
| Thea Pharma Inc. | 10 | $720 |
| Harrow Eye, LLC | 7 | $701 |
| Mallinckrodt Hospital Products Inc. | 6 | $456 |
| Quidel Corporation | 6 | $389 |
| Biogen | 1 | $360 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $254 |
| Eyepoint US, Inc. | 1 | $123 |
| Shire North American Group Inc | 1 | $122 |
| Mallinckrodt Enterprises LLC | 1 | $113 |
| Tearlab Corp | 1 | $97 |
| Sun Pharmaceutical Industries Inc. | 3 | $87 |
| Carl Zeiss Meditec, Inc. | 1 | $58 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$7,800
- TYRVAYA$2,195
- Oxervate$2,095
- TEPEZZA$2,000
- Spectralis$2,000
- XIIDRA$530
- Eye Health$472
- AcrySof IQ PanOptix$407
- ACTHAR$372
- MIEBO$299
- Clareon$293
- TRYPTYR$255
- DURYSTA$220
- VEVYE$150
- VYZULTA$149
- enVista MX60 IOL$149
- STELLARIS ELITE$149
- IC-8 Apthera IOL$138
- AMO PHACO NEEDLE$130
- IYUZEH$128
How this compares
$329,604 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 26 | $418 |
| Gabapentin | 16 | $137 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Miami
- Guillermo AmescuaMiami$962K
- Felipe MedeirosMiami$935K
- Jennifer LohMiami$606K
- Jaclyn KovachMiami$590K
- William TrattlerMiami$580K
- Wilfredo LaraMiami$526K
- Jayanth SridharMiami$525K
- Kendall DonaldsonMiami$351K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.